CHINA HEALTH GRP HD-10 (VNL1) - Net Assets
Based on the latest financial reports, CHINA HEALTH GRP HD-10 (VNL1) has net assets worth €78.42 Million EUR (≈ $91.68 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€110.02 Million ≈ $128.62 Million USD) and total liabilities (€31.60 Million ≈ $36.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See CHINA HEALTH GRP HD-10 net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €78.42 Million |
| % of Total Assets | 71.27% |
| Annual Growth Rate | -23.47% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.49 |
CHINA HEALTH GRP HD-10 - Net Assets Trend (2021–2024)
This chart illustrates how CHINA HEALTH GRP HD-10's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see CHINA HEALTH GRP HD-10 stock valuation.
Annual Net Assets for CHINA HEALTH GRP HD-10 (2021–2024)
The table below shows the annual net assets of CHINA HEALTH GRP HD-10 from 2021 to 2024. Also explore CHINA HEALTH GRP HD-10 (VNL1) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €69.72 Million ≈ $81.51 Million |
-17.18% |
| 2023-12-31 | €84.18 Million ≈ $98.42 Million |
-40.67% |
| 2022-12-31 | €141.88 Million ≈ $165.88 Million |
-8.80% |
| 2021-12-31 | €155.57 Million ≈ $181.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CHINA HEALTH GRP HD-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 446.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €137.86 Million | 195.96% |
| Total Equity | €70.35 Million | 100.00% |
CHINA HEALTH GRP HD-10 Competitors by Market Cap
The table below lists competitors of CHINA HEALTH GRP HD-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FINCANNA CAPITAL CORP.
F:4AL0
|
$582.22K |
|
Integragen
PA:ALINT
|
$582.39K |
|
PT Century Textile Industry Tbk
JK:CNTX
|
$582.44K |
|
Discovery Harbour Resources Corp
V:DHR
|
$584.17K |
|
Tupperware Brands Corporation
NYSE:TUPBQ
|
$581.63K |
|
OSX Brasil S.A
SA:OSXB3
|
$580.64K |
|
Lakshmi Precision Screws Limited
NSE:LAKPRE
|
$579.82K |
|
Crystal Amber Fund Limited
LSE:CRS
|
$579.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHINA HEALTH GRP HD-10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,819,000 to 70,353,000, a change of -14,466,000 (-17.1%).
- Other factors decreased equity by 14,466,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €0.00 | -0.0% |
| Other Changes | €-14.47 Million | -20.56% |
| Total Change | €- | -17.06% |
Book Value vs Market Value Analysis
This analysis compares CHINA HEALTH GRP HD-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.16 | €0.00 | x |
| 2022-12-31 | €0.14 | €0.00 | x |
| 2023-12-31 | €0.09 | €0.00 | x |
| 2024-12-31 | €0.07 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CHINA HEALTH GRP HD-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.44x
- Recent ROE (0.00%) is above the historical average (-14.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 23.35% | 43.45% | 0.43x | 1.25x | €20.77 Million |
| 2022 | -11.12% | -120.90% | 0.07x | 1.26x | €-30.06 Million |
| 2023 | -68.40% | -270.78% | 0.18x | 1.41x | €-66.50 Million |
| 2024 | 0.00% | 0.00% | 0.26x | 1.44x | €-7.04 Million |
Industry Comparison
This section compares CHINA HEALTH GRP HD-10's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,254,006,910
- Average return on equity (ROE) among peers: -29.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHINA HEALTH GRP HD-10 (VNL1) | €78.42 Million | 23.35% | 0.40x | $581.84K |
| IZOTROPIC CORP. (1R3) | $-3.07 Million | 0.00% | 0.00x | $8.79 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $4.18 Million | -188.49% | 2.68x | $879.62K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $22.68 Billion | 8.85% | 0.21x | $713.97 Million |
| Check-Cap Ltd (7CC) | $50.69 Million | -33.94% | 0.10x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $4.13 Billion | 30.56% | 1.08x | $286.80 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $27.08 Million | -42.15% | 0.94x | $2.36 Million |
| GENINCODE PLC LS -01 (9PL) | $7.90 Million | -70.37% | 0.49x | $6.02 Million |
| INOVIQ LTD. (EGQ0) | $19.62 Million | -45.73% | 0.10x | $14.07 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $945.17 Million | 27.74% | 0.93x | $7.52 Billion |
About CHINA HEALTH GRP HD-10
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People's Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research… Read more